Non-Dilutive Funding for Startups: Grants, Revenue Share and Other Ways to Raise Without Selling Equity

What non-dilutive funding means

Non-dilutive funding is money a startup raises without issuing new shares, so existing owners keep the same percentage of the company. The category includes grants, prizes, revenue-based financing, venture debt, and cash that customers pay you before you deliver. What they share is the absence of a new equity holder on your cap table.

That does not make the money free. Every non-dilutive source charges you in another currency: reporting duties, repayment, restrictions on how you spend, or a slice of future revenue. The useful question is not whether a source is dilutive but which cost you would rather carry: ownership, cash flow, or control over your own roadmap.

The five main sources, and what each one costs

Grants are the closest thing to free money. Public programs such as the US SBIR/STTR awards or the EU's EIC Accelerator fund research and development work, and there is no repayment and no equity. The price is paid in time: long applications, competitive selection, milestone reporting, and spending that must match the approved budget.

Revenue-based financing and venture debt are the two repayable instruments. RBF advances cash against recurring revenue and takes a fixed share of monthly revenue until a cap is reached; venture debt is a loan with fixed payments, usually after a priced round. Customer prepayment, such as annual plans paid upfront or a design-partner deposit, is the cheapest source when you can get it, because the only obligation is delivering the product. Prizes and competitions are small and unpredictable, so treat them as a bonus rather than a plan.

Each source has a different speed and a different set of strings attached. Grants are slow and restricted, prepayment is fast but depends on a customer who trusts you, and the repayable instruments are fast but turn into a monthly claim on your cash.

Grants versus an equity round: the real trade

A priced round and a grant solve the same problem, extending runway, but they charge different prices. Equity is fast to describe and expensive to give away, because every percentage point you sell is permanent. A grant is cheap in ownership and expensive in attention, and its money usually arrives as reimbursement after you have already spent it.

That reimbursement detail matters for cash planning. A grant that pays you back for approved costs in arrears does not help a startup with two months of runway left, because you have to float the spending first. Grants are strongest when you already have a runway buffer and a project that fits the program's definition of eligible work.

What non-dilutive money does to your runway

Runway is cash divided by monthly net burn, so a grant can help in two ways: it adds to cash, or it offsets part of the burn. Take a startup with $240,000 in the bank and $40,000 of monthly net burn, which is six months of runway. If a grant reimburses $10,000 a month of qualifying R&D costs over a year, effective net burn falls to $30,000 and the same cash lasts eight months.

The example is illustrative, but the shape is real. Repayable instruments work in the opposite direction. A revenue share of 6% on $50,000 of monthly revenue takes $3,000 a month back out of the business, which is why a repayable advance buys fewer months than its headline amount suggests. Always model the net effect on monthly burn, not just the size of the check.

When non-dilutive funding fits, and when it does not

It fits best when the project has a clear deliverable and a measurable output: a prototype to build, a clinical or technical validation to complete, a pilot with an institutional customer. It also suits startups that want to delay a priced round until traction improves the valuation, because every month bought without selling equity lets a later round happen at a better price.

It fits poorly when speed is the entire game. Applying for a grant while a competitor is closing the market is a slow answer to a fast problem, and a startup that bends its roadmap to match a program's scope can end up building what the grant wants instead of what customers want. The same warning applies to repayable instruments: a fixed obligation on top of weak unit economics only shortens the path to the wall.

Common mistakes founders make

The first mistake is treating a grant as a revenue substitute. Grant money funds a defined project; it does not prove anyone wants the product, and investors read a company that lives on grants differently from one that lives on customers. The second is ignoring the reimbursement gap and spending the cash needed to qualify before the payment arrives.

The third is stacking obligations. A startup that takes a revenue share, a venture debt facility and a grant with strict spending rules has quietly handed several parties a claim on its calendar and its cash. Keep a running view of what you owe, in money and in reporting, before adding one more instrument. Funding choices also feed the cap table later, so compare any option against the dilution a priced round would cost.

Practicing the trade-off in Founder Runway

A funding decision is easy to analyze and hard to feel until cash is on the line. In Founder Runway, a run lasts 20 turns, every decision has four options, and you pick a B2B, B2C or B2G model and a starting stage from Pre-Seed to Series A. Along the way you balance cash, runway and cap table, so a choice that protects ownership can still cost you months.

Runs can end in failure, a promising outcome, EBITDA positive or high-value exit potential, and the way you funded the early turns shapes which one you reach. The game is a rehearsal space, not financial advice. It will not tell you which grant to apply for, but it makes the cost of each trade visible before real money moves.